Overview

• LC16m8, originally developed for smallpox and approved for mpox in 2022, has demonstrated robust immunogenicity and a favorable safety profile in new trials.
• Comprehensive research involving mice, non-human primates, and human volunteers highlights the vaccine’s ability to induce strong immune responses and reduce viral replication.
• In human trials, LC16m8 elicited neutralizing antibodies against multiple mpox variants without serious adverse effects, supporting its broad protection and tolerability.
• Findings suggest the vaccine is scalable and suitable for rapid deployment in regions facing high mpox transmission risk, particularly in Africa.
• Further studies are required to optimize dosing and evaluate its efficacy in immunocompromised and naive populations to maximize global impact.